-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2025-522914-22-00
3
2026-02-11
Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2024-515948-23-00
5
2026-02-06
Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
-
2024-515695-13-00
11
2026-02-02
elderly patients hospitalized for viral infections
-
2023-510253-42-00
4
2026-01-28
Adult patients aged 18 and over with unicentric hyalino-vascular Castl
-
2024-516371-32-00
5
2026-01-28
insomnia
-
2025-521909-40-00
4
2026-01-28
Patients with metastatic or locally advanced HER2-low triple-negative
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2022-501902-36-00
5
2026-01-15
spina bifida
-
2024-520208-25-00
4
2026-01-15
Still’s disease
-
2024-511084-28-00
11
2026-01-12
Hypertrophic Cardiomyopathie
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2024-517653-27-00
4
2025-12-17
Prostate Cancer
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-514763-25-01
1
2025-12-04
spinocerebellar ataxia type 2
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521398-15-00
5
2025-12-04
Immune system diseases
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)